Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) — free guideline decision tool
This tool selects the preferred glucose-lowering add-on for type 2 diabetes by comorbidity, layering SGLT2 inhibitors and GLP-1 receptor agonists onto metformin per Chinese T2DM guidelines and the ADA.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Comorbid ASCVD or high cardiovascular risk | Yes |
|---|---|
| Comorbid heart failure | Yes |
| Comorbid chronic kidney disease (CKD) | Yes |
| eGFR (optional, for SGLT2i applicability) | 60 mL/min/1.73m² |
→Preferred add-onPreferred SGLT2i
- Comorbidities：ASCVD/high-risk, heart failure, CKD
- Base therapy：Lifestyle intervention + metformin (continued unless contraindicated)
- Preferred add-on：Preferred SGLT2i
| Comorbid ASCVD or high cardiovascular risk | No |
|---|---|
| Comorbid heart failure | No |
| Comorbid chronic kidney disease (CKD) | No |
| eGFR (optional, for SGLT2i applicability) | 60 mL/min/1.73m² |
→Preferred add-onIndividualized dual therapy
- Comorbidities：none
- Base therapy：Lifestyle intervention + metformin (continued unless contraindicated)
- Preferred add-on：Individualized dual therapy
Common questions
What is Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice)?
This tool selects the preferred glucose-lowering add-on for type 2 diabetes by comorbidity, layering SGLT2 inhibitors and GLP-1 receptor agonists onto metformin per Chinese T2DM guidelines and the ADA.
How is Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) calculated? What is the core formula?
Decision logic: heart failure/CKD → SGLT2i (GLP-1RA if eGFR < 30); ASCVD/high risk → GLP-1RA or SGLT2i regardless of HbA1c; otherwise individualized add-on by hypoglycemia risk, weight, and cost.
When is Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) used?
Use when escalating T2DM therapy: comorbid heart failure or CKD favors an SGLT2i, ASCVD or high cardiovascular risk favors a GLP-1RA or SGLT2i, and the absence of these favors individualized dual therapy.
What are the key clinical points for Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice)?
Cardiorenal-protective agents are chosen for the comorbidity even when HbA1c is at target — the indication is organ protection, not just glucose control. (original synthesis · not guideline verbatim) At eGFR < 30 most SGLT2i are off-label, so a GLP-1RA becomes the preferred cardiorenal add-on. Metformin and lifestyle remain the foundation unless contraindicated.
What are the limits and cautions when using Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice)?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) calculated in practice? Can you show a worked example?
Inputs: Comorbid ASCVD or high cardiovascular risk Yes, Comorbid heart failure Yes, Comorbid chronic kidney disease (CKD) Yes, eGFR (optional, for SGLT2i applicability) 60 mL/min/1.73m² → Result: Preferred add-on Preferred SGLT2i（Comorbidities: ASCVD/high-risk, heart failure, CKD, Base therapy: Lifestyle intervention + metformin (continued unless contraindicated), Preferred add-on: Preferred SGLT2i） Inputs: Comorbid ASCVD or high cardiovascular risk No, Comorbid heart failure No, Comorbid chronic kidney disease (CKD) No, eGFR (optional, for SGLT2i applicability) 60 mL/min/1.73m² → Result: Preferred add-on Individualized dual therapy（Comorbidities: none, Base therapy: Lifestyle intervention + metformin (continued unless contraindicated), Preferred add-on: Individualized dual therapy）
Run Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) now
This tool selects the preferred glucose-lowering add-on for type 2 diabetes by comorbidity, layering SGLT2 inhibitors and GLP-1 receptor agonists onto metformin per Chinese T2DM guidelines and the ADA.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.